Results of unrelated cord blood transplantation (UCBT) in childhood @entity3052 ( @entity3052 ) have not been previously reported. We analyzed 95 @entity1 receiving UCB transplants for @entity3052 (20 in first complete remission [ @entity3432 ], 47 in @entity10911 , and 28 in more advanced stage). Poor prognosis cytogenetic abnormalities were identified in 29 cases. Most @entity1 received a 1 or 2 HLA antigens-mismatched UCB transplants. The median number of collected nucleated cells (NCs) was 5.2 x 107/kg. Cumulative incidence (CI) of neutrophil recovery was 78% +/- 4%, @entity2132 ( @entity2132 ) was 35% +/- 5%, and 100-day transplantation-related mortality (TRM) was 20% +/- 4%. In multivariable analysis, a collected NC dose higher than 5.2 x 107/kg was associated with a lower 100-day TRM. The 2-year CI of relapse was 29% +/- 5% and was associated with disease status. The 2-year @entity1778 ( @entity1778 ) was 42% +/- 5% (59% +/- 11% in @entity3432 , 50% +/- 8% in @entity10911 , and 21% +/- 9% for @entity1 not in CR). @entity1 with poor prognosis cytogenetic features had similar @entity1778 compared with other @entity1 (44% +/- 11% vs 40% +/- 8%). In @entity10911 , @entity1778 was not influenced by the length of @entity3432 (53% +/- 11% in @entity3432 < 9.5 months compared with 50% +/- 12% in later relapses). We conclude that UCBT is a therapeutic option for @entity1 with very poor-prognosis @entity3052 and who lack an HLA-identical sibling.

Unrelated cord blood transplantation for childhood XXXX : a Eurocord Group analysis.

@entity1 :: ('9606', 'Species') :: ['children', 'patients', 'Children'] @entity3432 :: ('1378', 'Gene') :: ['CR1'] @entity10911 :: ('1380', 'Gene') :: ['CR2'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia', 'AML'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemia-free survival', 'LFS'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['GVHD', 'acute graft-versus-host disease']
@entity3052 :: (MESH:D015470,Disease) :: ['acute myeloid leukemia']
